Sanofi's Commitment to Research and Identify Treatments for Cancer Patients

SanofiSanofi (EURONEXT: SAN and NYSE: SNY) announced that data from eight compounds in the company's robust oncology portfolio will be showcased in more than 100 abstracts at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 3-7, 2011.

Data presentations highlight the Sanofi Oncology pipeline in both solid tumors and hematologic malignancies. New research from early through late stage development will be reported, including data on cabazitaxel, docetaxel and oxaliplatin, as well as on investigational compounds iniparib and semuloparin.

"Sanofi fully supports this year's ASCO Presidential Theme - Patients, Pathways and Progress. Our connection to the patient inspires us to partner with leading experts to exchange ideas that will help us discover innovative solutions to improve patient outcomes," said Debasish Roychowdhury, MD, Senior Vice President and Head of Global Oncology Division. "Sanofi is committed to ASCO and its mission."

About Iniparib (BSI-201)
BSI-201 is a novel investigational oncology agent that is in Phase III trials for patients with squamous non-small cell lung cancer, as well as in Phase II trials for patients with breast, lung and other cancers. Iniparib is the United States Adopted Name (USAN) for BSI-201.

About Cabazitaxel
Cabazitaxel is a semi-synthetic taxane and works differently than docetaxel and paclitaxel. An antineoplastic agent, it acts by disrupting the microtubular network in cells. It binds to tubulin and promotes the assembly of tubulin into microtubules while simultaneously inhibiting their disassembly. This leads to the stabilization of microtubules. Cabazitaxel demonstrated a broad spectrum of antitumor activity against advanced solid tumours xenografted in mice. Cabazitaxel is active in docetaxel sensitive tumors. In addition, cabazitaxel demonstrated activity in tumour models insensitive to chemotherapy, including docetaxel.

About Semuloparin
Semuloparin is an investigational, selectively engineered anticoagulant that belongs to the ultra-lowmolecular-weight heparin (ULMWH) class. Semuloparin has a novel anti-thrombotic profile resulting from an enriched antithrombin binding site and high-activity against factor Xa and residual activity against factor IIa. A large phase III clinical study (SAVE ONCO study) investigated semuloparin in cancer patients receiving chemotherapy that has been completed. The SAVE ONCO study assessed the efficacy and safety of semuloparin for the prevention of symptomatic VTE, Pulmonary Embolism and VTE related death in cancer patients receiving chemotherapy. There is currently no product registered in this indication.

About BiPar Sciences
BiPar Sciences is a biopharmaceutical organization dedicated to pioneering novel tumor-selective therapies designed to address urgent unmet needs of cancer patients. Located in South San Francisco, California, BiPar is a wholly owned subsidiary of Sanofi.

About Sanofi Oncology
Based in Cambridge, Massachusetts, and Vitry, France, Sanofi Oncology is translating science into effective cancer therapeutics to address unmet medical needs for patients with cancer. Starting with a deep understanding of the mechanisms by which cancer develops, grows and spreads, the company employs innovative approaches in drug discovery, clinical development and partnerships to bring the right medicines to the right patients with the goal of helping cancer patients live healthier and longer lives. Sanofi Oncology is committed to the pursuit of science and innovative cancer therapies. We believe in partnership with leading experts, and combining that expertise with our own internal scientific strength and heritage. There are currently more than 10 compounds in clinical development including small molecules and biological agents.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

How old antibiotic compounds could become tomorrow…

As the fight against drug-resistant infections continues, University of Leeds scientists are looking back at previously discarded chemical compounds, to see if any could ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]